Immune Checkpoint Inhibitor-Induced Rapid Decline in Hepatitis B Virus Markers Improves the Prognosis of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients
ICIs demonstrate dual therapeutic effects in HBV-related HCC, significantly reducing multiple HBV markers while concurrently enhancing prognosis in combination with antiviral therapy, emphasizing the importance of sustained virological suppression for optimal HCC outcomes.
Authors
- Kunyuan Wang
- DingLi Liu
- Yabing Guo
- Minghui Zhu
- Ying Xia (ORCID: https://orcid.org/0000-0002-5066-7407)
- Xiaoyun Hu
- Huaiyu Chen
- Rong Fan
- Yun Zhu (ORCID: https://orcid.org/0000-0002-7867-5249)
- Mengya Zang
- Yujie Ran
- Jie Chen (ORCID: https://orcid.org/0000-0003-0266-0929)
- Fang Liu
- Qi Li
- Qian Zhao
- Xiaowei Chen
- Shuai Kang
- Hongyan Liu
- Ying Wang
Institutions
- Ministry of Education of the People's Republic of China (CN)
- Guangdong Provincial Center for Disease Control and Prevention (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1093/infdis/jiag036
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00